Effectiveness of Thuja occidentalis in Verruca Vulgaris: A Case Series Study
Abstract
Background: Verruca vulgaris is a benign epithelial proliferation caused by human papillomavirus (HPV), commonly affecting children and young adults. Although spontaneous regression may occur, many cases persist or recur despite conventional treatments such as cryotherapy and keratolytics. Homoeopathy considers warts predominantly under the sycotic miasm, and Thuja occidentalis is regarded as a principal remedy for warty excrescences. Materials and Methods: This prospective interventional case series was conducted at C.D. Pachchigar Homoeopathic Medical College and Hospital. Three clinically diagnosed cases of verruca vulgaris were enrolled. Detailed case taking was performed as per aphorisms 83–104 of the Organon of Medicine. Remedy selection was based on totality of symptoms. Thuja occidentalis was prescribed in centesimal potency internally, along with external application of Thuja ointment. Follow-up was conducted at regular intervals. Treatment effectiveness was assessed using the MYMOP2 (Measure Yourself Medical Outcome Profile 2) scale. Results: Two out of three cases (66.6%) demonstrated significant improvement, with one case achieving complete resolution (100% improvement). One case showed mild improvement (11.82%). No recurrence or adverse effects were observed during the follow-up period. Higher potency (1M) cases showed comparatively better clinical response than 200 potency. Conclusion: The findings suggest that Thuja occidentalis, prescribed on homoeopathic principles and administered both internally and externally, may be effective in the management of verruca vulgaris. However, due to the small sample size, larger controlled studies are required to substantiate these findings.
Fields of Study & Subjects
Complementary and Alternative Medicine Studies
Medicinal Plant Research
Dermatologic Treatments and Research
Publication details
- Journal / source
- Zenodo (CERN European Organization for Nuclear Research)
- Publication date
- 3 March 2026
- Language
- EN